Journal of the American Heart Association
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial
Trial in peopleBiomarkers
Papers by Jean-François Tamby
4 results
- AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results From the ATTRibute-CM Study
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Trial in peopleInterventions